Explore Stanford technologies available for licensing:

Rat monoclonal antibody BZ194 specifically recognizes mouse serpentine receptor mCMKLR1 (aka ChemR23, DEZ). mCMKLR1 is a novel protein possessing high homology with members of the chemoattractant receptor family, and binds the chemoattractant chemerin.

Stanford researchers have created the orthoCD3 T cells, by engineering T cells to resist depletion from anti-CD3 antibodies during lymphodepletion, thereby, enhancing the efficacy of T cell therapies for cancer, autoimmune disorders, and transplant rejection.

Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.

Aging-associated mitochondrial dysfunction (mito-dysfunction) affects every cell system in our body. Mito-dysfunction includes reduced quality of mitochondrial DNA (mtDNA), irregular generation of reactive oxygen species, and membrane potential.

Activation of hedgehog signaling pathway can facilitate stem cell proliferation and holds great promise in regenerative medicine for a variety of indications.

Stanford researchers have suggested ganglioside GM2, which is upregulated with the loss of ganglioside GD2, as a safe alternative target for antibodies and CAR-T cells for cancer immunotherapy.

Stanford researchers have developed recombinant polypeptides targeting growth factor beta (TGF-?) receptor 1 and TGF?

Stanford researchers have developed a novel inhibitor-based conditioning regimen that safely and effectively induces immune tolerance.

Researchers at Stanford have developed a novel strategy to enhance vaccine efficacy using mRNA lipid nanoparticles (LNPs) encoding immunostimulatory cytokines.

HECA-452: ATCC Number HB-11485:

Stanford researchers have developed new imaging agents for the detection of the CA6 epitope in vivo in cancer patients.

This antibody(MEL-14) is specific for a single class of lymphocyte surface molecules that appear to mediate recognition of lymph node high endothelial venules and that appear to be required for lymphocyte homing to lymph nodes in vivo.

MECA-99 is a previously unpublished EC-specific rat monoclonal antibody (mAb), which in most settings selectively stains capillary EC in adult mice.

Stanford researchers in the Cochran Lab have patented a potential pancreatic cancer therapeutic approach using novel agents that bind tightly to and inhibit a cancer factor called LIF (leukemia inhibitory factor).